← All trials
NCT05608499
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 4, 2022
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Nov 8, 2022
- Last posted
- Nov 8, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Bausch Health CompaniesCollaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.